Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Med Mal Infect ; 46(7): 385-389, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27427280

ABSTRACT

OBJECTIVE: The increasing resistance of Helicobacter pylori to clarithromycin led to developing new eradication treatment regimens. The objective of our observational study was to determine the proportion of H. pylori strains resistant to clarithromycin in infected patients in Reunion Island and to suggest a first-line treatment in agreement with the local ecology. PATIENTS AND METHODS: We included 200 patients who underwent esophagogastroduodenoscopy at the University Hospital of Saint-Pierre from February to July 2014. H. pylori was isolated from 73 patients. RESULTS: A wild-type susceptibility profile to clarithromycin was observed in 64 isolates (87.7%) and nine isolates (12.3%) had a resistant mutation profile. CONCLUSION: With a proportion of resistant strains below the critical threshold of 15%, physicians in Reunion Island may continue to prescribe the usual treatment regimen as a first-line option (clarithromycin, amoxicillin, and proton pump inhibitor for 14 days).


Subject(s)
Anti-Bacterial Agents/therapeutic use , Clarithromycin/pharmacology , Dyspepsia/epidemiology , Gastritis, Atrophic/microbiology , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Adenocarcinoma/epidemiology , Adenocarcinoma/microbiology , Amoxicillin/therapeutic use , DNA, Bacterial/genetics , Drug Resistance, Microbial/genetics , Drug Therapy, Combination , Dyspepsia/etiology , Gastric Fundus/microbiology , Gastritis, Atrophic/drug therapy , Gastritis, Atrophic/epidemiology , Helicobacter Infections/drug therapy , Helicobacter Infections/epidemiology , Helicobacter pylori/genetics , Helicobacter pylori/isolation & purification , Humans , Metaplasia , Mutation , Proton Pump Inhibitors/therapeutic use , Pyloric Antrum/microbiology , Reunion/epidemiology , Stomach Neoplasms/epidemiology , Stomach Neoplasms/microbiology
2.
Bull Soc Pathol Exot ; 95(2): 66-70, 2002 Jun.
Article in French | MEDLINE | ID: mdl-12145959

ABSTRACT

The aims of this paper were to assess resistance of Helicobacter pylori to antibiotics included in the so-called French triple regimens and to identify the possible causes of therapeutic failure in Reunion island. Antibiotic resistance was determined for 109 strains. All the strains were sensitive to amoxicillin and tetracycline, 93.6% were sensitive to ciprofloxacin, 92.7% to erythromycin and 60.6% to metronidazole. Fifty three patients who had previously tested positive for H. pylori received for one week regimen of amoxicillin (1 g bd), clarithromycin (0.5 g bd) and omeprazole (20 mg bd). Eradication rate after therapy was of 73.6%. Therapeutic failure was analysed for 9 patients using random amplified polymorphic DNA and the presence or not of antibiotic resistance. One cause of failure is clarithromycin resistance. These data show that triple therapy can be used in Reunion Island. In case of failure, sensitivity must be detected because the rate of resistance to metronidazole is over 30%.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Helicobacter Infections/drug therapy , Helicobacter pylori/drug effects , Stomach Ulcer/microbiology , Amoxicillin/therapeutic use , Anti-Ulcer Agents/therapeutic use , Chi-Square Distribution , Ciprofloxacin/therapeutic use , Clarithromycin/therapeutic use , Confidence Intervals , DNA, Bacterial/analysis , Drug Resistance, Bacterial/genetics , Erythromycin/therapeutic use , Female , Helicobacter pylori/genetics , Humans , Male , Metronidazole/therapeutic use , Middle Aged , Omeprazole/therapeutic use , Penicillins/therapeutic use , Random Amplified Polymorphic DNA Technique , Reunion , Stomach Ulcer/drug therapy , Tetracycline/therapeutic use , Treatment Failure
3.
Rev Med Interne ; 13(3): 205-10, 1992.
Article in French | MEDLINE | ID: mdl-1410902

ABSTRACT

The number of people travelling of the tropical countries is in constant progression and today represents about 5% of the population of the developed countries. Mortality is mainly accidental. Morbidity essentially concerns transmissible diseases. Diarrhoeal symptoms occur in 20-55% of travellers, are bacterial in 2 cases out of 3, and can be prevented. Cholera should soon have an efficient oral vaccine. Hepatitis A is frequent in some travellers (2-3%) and can be prevented by vaccination. Hepatitis E is beginning to be observed. Strongyloidiasis can in some cases evolve to serious complications; it may be latent, so should be sought systematically after any visit to the tropics. Most affections on returning to the industrialised world concern paludism of the Plasmodium falciparum type, leading to a still high mortality rate of 400 per year in Europe, while the preventive and curative means available are sufficient. Any fever should therefore be suspected and suitable treatment given. Other causes of fever are acute viral hepatitis, typhoid fever, the arboviroses, and numerous other conditions. Dermatoses represent the third reason for consultation on returning. These mainly concern pruriginous symptoms with filariases and abnormal hosts being evidenced. Furunculous lesions indicate a diagnosis of cutaneous leishmaniosis or myases. Any form of pruritus should suggest a diagnosis of HIV infection, or pruritus should suggest a diagnosis of HIV infection, or particularly trypanosomiasis. The risk of sexually transmissible disease is overall 6-fold higher in tropical travellers; advice before travelling is therefore of paramount importance. Should a seropositive subject travel to the tropics?(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Communicable Diseases/epidemiology , Travel , Tropical Climate , Adult , Diarrhea/epidemiology , Female , France/epidemiology , Hepatitis/epidemiology , Humans , Intestinal Diseases, Parasitic/epidemiology , Malaria/epidemiology , Male , Sexually Transmitted Diseases/epidemiology , Skin Diseases/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...